|
| Wednesday, 7 December 2022, 06:00 HKT/SGT | |
| | | | 來源 NUNMN | |
|
|
香港, 2022年12月7日 - (亞太商訊) - NUNMN隸屬Nulab Technology Ltd.,是一家加拿大公司,提供99.5%的純NMN保健品,公司發展迅速,規模壯大,現已進駐香港市場。以往銷售市場僅限加拿大和美國各地,公司為擴大銷售業務,面向香港市場及消費者推出NMN保健品,成為其進入亞洲市場的切入點。 在最近的一次採訪中,Nulab Technology Ltd. 總裁Alan M.表示,「每年,該保健品都會受到來自世界各地大量新用戶的青睞。我們收到來自各大洲客戶的諮詢。所有產品均獲加拿大衛生部授權,能有效提升健康水平,滿足消費者需求。香港只是我們全球業務擴展計劃二階段的一部分!」
據Alan M.介紹,NUNMN和Nulab Technology Ltd.近期的業務擴展只是戰略規劃的開始。公司已着手市場調研,以便在歐洲和南美市場能站穩腳跟。
關於NUNMN和Nulab Technology Ltd. Nulab Technology Ltd. 總裁表示,公司最初在加拿大以保健品供應商的身份開始發展,現已通過其全球網絡及網站為世界各地客戶提供服務。
如今,公司在加拿大具有穩定的客戶,且美國市場增長勢頭良好,已為業務擴展打下堅實的基礎。經過幾個月的研究、測試和籌備,網上商店正式向香港市場開放。
NUNMN是一家領先的美容健康公司,在加拿大和美國設有辦事處,即將在香港設立辦事處。公司致力於重新定義人們的健康與年齡。
哈佛大學醫學院的遺傳學教授David Sinclair發現,NMN(99.5%)可以為人體廣泛吸收,從而改善健康與新陳代謝,大腦功能和心血管也因此得到改善。
煙酰胺單核苷酸(NMN)分子會轉化為化學成分煙酰胺腺嘌呤二核苷酸(NAD+),該化學成分非常重要,眾所周知。人體吸收NAD+為多個體內活動提供燃料,包括DNA損傷修復、能量的生產以及免疫力的提高。因此,NAD+有助於維持高代謝,並保持整個身體機能的健康。
媒體聯繫人: Alan M. 郵箱:hello@nunmn.com 網址:https://nunmn.com/zh/ 電話:1(888) 666-6851
話題 Press release summary
部門 食品, 美容/护肤
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network
|
|
|
|
|
|
 |
|
Latest Press Releases
Focus Graphite Appoints Renowned Battery Executive Dr. Sunho Kang as Strategic Advisor for Cell Technology
Dec 3, 2025, 18:09 HKT/SGT
|
|
|
Anime Tokyo Station: Celebrating the 25th Anniversaries of Two Popular Anime with an Anniversary Joint Exhibition Starting November 15
Wednesday, December 3, 2025 10:30:00 AM
|
|
|
Polytek Engineering Selected as ORCA's Exclusive Distributor and Service Partner for Hong Kong
Dec 3, 2025, 07:00 HKT/SGT
|
|
|
Doubleview Provides Cobalt Resource Summary for the Hat Polymetallic Deposit in Advance of Updated MRE and PEA
Dec 2, 2025, 21:59 HKT/SGT
|
|
|
OpenAI Joins the Global Anti-Scam Alliance as Foundation Member to Strengthen Global Response Against AI-Enabled Scams
Dec 2, 2025, 21:00 HKT/SGT
|
|
|
Digital Realty and BW Digital Partner to Support Expansion of Cross-Border Connectivity Between Singapore and Batam
Dec 2, 2025, 15:49 HKT/SGT
|
|
|
GEN Announces New Positive Phase 1 Trial Data of the Investigational Drug SUL-238 for Alzheimer's and Other Neurodegenerative Diseases
Dec 2, 2025, 13:00 HKT/SGT
|
|
|
AdipoLABs Opens New Regional Office, Signs Two MoUs With University of Cyberjaya to Advance Healthcare Innovation
Dec 2, 2025, 12:22 HKT/SGT
|
|
|
Fujitsu achieves high-precision, long-duration molecular dynamics simulation for all-solid-state battery interphases with over 100,000 atoms
Monday, December 1, 2025 10:04:00 PM
|
|
|
Fujitsu develops multi-AI agent collaboration technology to optimize supply chains, launches joint trials
Monday, December 1, 2025 9:43:00 PM
|
|
|
|
|
More Press release >> |
|
|
|